Introduction R EYE's syndrome is a severe disorder almost entirely limited to children and characterized by encephalopathy and fatty infiltration of the viscera, especially the liver. Typically the child seems to be recovering from a viral or other febrile illness when severe vomiting and altered consciousness occur. Unexpected protracted vomiting following a prodromal influenza-like illness, chicken pox or other febrile condition is characteristic, but infants and children under three years of age may have minimal vomiting and no clear prodrome. The condition should be suspected when, in these circumstances, there are signs of disturbed brain function including lethargy, staring, stupor, agitated delirium, screaming, rapid respiration, extensor spasms, decerebrate rigidity, involuntary movements and coma. Hypoglycaemia and hepatomegaly are sometimes present in Reye's syndrome as are grossly elevated serum transaminase levels, usually associated with raised blood ammonia levels, despite the absence of jaundice. The outcome is frequently death or survival with severe brain damage.
The British Reye's Syndrome Surveillance Scheme was started in August 1981 and in the first four years of surveillance 229 cases of Reye's syndrome were reported. One hundred and fifteen of these children died. In the United Kingdom the annual incidence has varied from 0.3 to 0.7 per 100 000 children under 16 years of age during the surveillance period. In view of the poor prognosis, and the fact that early treatment can be effective, a high index of suspicion is essential, even though the illness is rare. To achieve early diagnosis the condition should be suspected by the general practitioner and emergency liver function tests, prothrombin time estimations and measurements of blood ammonia levels should be undertaken immediately following urgent admission to hospital.
The initial treatment comprises infusions of 10% glucose solution to provide 70% of maintenance fluid requirements, estimation and correction of altered blood sugar values, maintenance of a proper airway and normalization of abnormal blood gas levels. Urgent measures to control raised intracranial pressure should be instituted while arrangements are made for transfer to a paediatric intensive care unit with facilities for measuring intracranial pressure accurately. Highly specialized techniques for controlling the grossly abnormal blood and tissue biochemistry produced by the syndrome have been described. 1 The Centre of Disease Control in the USA obtained the assistance of outside consultants to review these four studies which all had methodological problems such as selection bias, inappropriate control selection, recall bias and protopathic bias. On the basis of this review the US Food and Drug Administration concluded that the studies did not establish a conclusive link between the use of aspirin and the development of Reye's syndrome. In 1982, at the instigation of the Food and Drug Administration, the US Public Health Service developed a plan for a much larger study designed to overcome these methodological difficulties. The Food and Drug Administration also instituted an educational programme aimed at the general public and the health community warning against the use of aspirin in children who had suffered from influenza and chicken pox.
In 1984 the preliminary results from the pilot phase of the Public Health Service study became available and the full report7 was published in October 1985. Thirty patients with Reye's syndrome, whose diagnosis had been confirmed by an expert panel, and 145 controls were matched for age, race, and antecedent illness and selected from the same hospital, emergency room or school or identified by random digit dialling. Significantly more cases, 28 (93%) out of 30, than members of each of the four control groups or all controls combined, 66 (46'7o) out of 145, had received salicylates during the antecedent illness. (The odds ratio of all 30 cases versus all controls was 16.1, the lower 95%o confidence limit was 4.6.)
The British Reye's Syndrome Surveillance Scheme was started in 1981 as a joint activity run by the British Paediatric Association and the Public Health Laboratory Service Communicable Disease Surveillance Centre. In 1985 the Committee on Safety of Medicines was able to consider the preliminary results of the US Public Health Service pilot study and the data then available from the British scheme. It was apparent that Reye's syndrome in the UK differs from the clinical picture in the USA. The median age of 14 months in the UK was much less than in the USA; there were no obvious winter peaks in the number of reports of Reye's syndrome in the UK and no significant association with influenza. In the UK study there was a lower incidence of a clearly defined prodromal illness but the mortality was substantially higher than in the American studies.
None of the studies mentioned so far proved a direct link between the use of aspirin and the occurrence of Reye's syndrome. The situation was therefore kept under the closest scrutiny. In 1986 additional data, now being prepared for publication, became available from the British study. These data, reviewed in confidence by the Committee on Safety of Medicines, added to the weight of evidence already available and formed an appropriate basis for action. The factor that was persuasive was that all six available studies showed a finding in the same direction and suggested, albeit with varying degrees of significance, an association between the use of aspirin and the development of Reye's syndrome in some children. British Reye's Syndrome Surveillance Scheme study data During this study Dr Susan Hall, the principal investigator, and her colleagues interviewed the parents of 106 of the 229 reported cases in order to obtain a detailed review of possible aetiological factors. Careful analysis has shown that by ranking the Reye's syndrome subjects in groups reflecting the degree of confidence in the diagnosis, a clear trend is established showing that a greater proportion of the children with the most clear-cut diagnosis had taken aspirin; conversely, a smaller proportion had taken aspirin in the groups in which the diagnosis was less certain. Publication of the detailed data underlying this association is, of course, eagerly awaited because the analysis, ingenious in its own right, is unaffected by most of the biases introduced into earlier studies and is independent of any statistical difficulties in comparing cases and controls. This is especially important in the British Reye's Syndrome Surveillance Scheme study in which a comparison group of patients was studied but these subjects were not formal case controls.
Recent information
Remington and colleagues8 have studied the decrease in the numbers of cases of Reye's syndrome and the use of aspirin in Michigan over the period 1979-84 and have produced data which strongly suggest that a reduced use of aspirin may be associated with a decrease in the incidence of Reye The letter was despatched slightly earlier than had been planned owing to media reports that some such announcement was imminent. These reports negated the Committee's express intent of notifying the medical and pharmaceutical profession 48 hours or so before general advice was issued. The Chairman's letter also announced the industry decision that paediatric aspirin products would be withdrawn from sale.
On 10 June the Government's Chief Medical Officer held a press conference and this was followed by a press announcement issued by the Aspirin Foundation in consultation with the Department of Health and Social Security. On 14 June, the article 'Reye's syndrome and aspirin"'I summarized the available data and emphasized the fact that, whereas all four of the separate American studies had shown a positive association between aspirin consumption and the development of Reye's syndrome, no less than three of these studies had shown a negative association with paracetamol. The important point was also made that most of the British patients with Reye's syndrome had been aged under six years and 93% under 12 Paediatric paracetamol elixir has for some time been considered preferable to aspirin for infants and the present action, in effect, extends this statement throughout the whole period of childhood. The disadvantage of substituting paracetamol for aspirin is that overdosage with paracetamol is particularly dangerous as it may cause hepatic damage which is sometimes not apparent for four to six days. Doctors should therefore consider coupling their advice regarding the use of aspirin in children under 12 year of age with warnings that the conventional doses of paracetamol should in no case be exceeded. The Committee on Safety of Medicines and its Secretariat have made careful arrangements to monitor the number of reported cases of paracetamol overdose.
Conclusion
Assessment of the effects of the present action to restrict the use of aspirin in children aged under 12 years is clearly of crucial importance. Doctors are asked to be particularly diligent in reporting suspect adverse reactions to paracetamol by means of the yellow card scheme and, while it is perhaps appropriate that doctors should be on their guard against being influenced in diagnosing Reye's syndrome by their knowledge of whether or not aspirin has been given, it is of special importance that suspect cases of Reye's syndrome should be reported to the British Reye's Syndrome Register (telephone 01-200 6868).
It is possible that the number of cases of Reye's syndrome suspected may now increase (rather than diminish) owing to the increased awareness of the profession. Thus care must be exercised in interpreting future statistics on the apparent incidence of the condition.
It is hoped that the advice of the Committee on Safety of Medicines on restricting the use of aspirin in children under 12 years of age will reduce the levels of mortality and morbidity caused by Reye 
